Furthermore, a clear tumour dose-response relationship in the context of PSMA-RLT has been evidenced by Violet et al. Among 30 patients treated with fixed-activity 177Lu-PSMA-617, those who biochemically responded (i.e. prostate-specific antigen decline > 50%) received a median mean tumour absorbed dose of 14.1 Gy, as compared with 9.6 Gy for those who did not [36]. This evidence concerns the gene FOLH1 and neoplasm.